Skip to content
Search

Latest Stories

Sigma Pharmaceuticals partners with BoxxDocks to boost efficiency and sustainability

Sigma Pharmaceuticals partners with BoxxDocks to boost efficiency and sustainability

Through this partnership, Sigma aims to bolster its ESG strategy and accelerate its commitment to NHS net zero objectives

Sigma Pharmaceuticals, a leading pharmacy wholesaler and distributor in the UK, has joined hands with logistics technology innovator, BoxxDocks, to enhance efficiency and sustainability across its warehouse and transport operations.


Through this collaboration, Sigma will pioneer the use of BoxxDocks' cutting-edge tracking technology in the pharmaceutical sector, thereby improving asset visibility and management, a first-of-its-kind initiative in the industry.

Considered to be the first of its kind in the supply chain and logistics industry, BoxxDocks’ technology offers data-driven, granular track and trace solutions that “not only addresses the critical issue of inventory loss but also paves the way for cost savings and environmental benefits.”

By providing real-time data on asset location and movement, it empowers B2B distributors to “map their entire supply chains with unprecedented accuracy and efficiency.” This capability can significantly enhance operational efficiency and reduce costs by optimising asset utilisation and minimising loss, the company noted.

Rajiv Shah, Procurement and Innovation Officer at Sigma, said that the partnership with BoxxDocks will help accelerate their commitment to sustainability and achieving NHS net zero objectives.

“By having the ability to track our assets, we'll be able to minimise our environmental footprint by significantly reducing single-use materials, cutting down on the use of disposable packaging, while streamlining our distribution processes,” he added.

Additionally, BoxxDocks' innovative tracking technology enhances transit security and reduces waste by promoting reusable assets over single-use materials, thereby cutting environmental and financial impacts.

BoxxDocks CEO Alessandro Attanzio emphasised that their mission is to help enhance B2B distribution by offering smart, sustainable and cost-saving solutions.

He said: “We’re delighted to be working with Sigma Pharmaceuticals, which is a forward-thinking company with a passion for innovation that rivals our own. We look forward to continuing our journey of innovation together, demonstrating a model of best practice for pharma distribution.”

By partnering with Sigma, Attanzio said they have further refined their technology to meet the specific needs of the pharmaceutical sector.

Attanzio reiterated that their technology can “transform operations, reduce cost and environmental impact, and help drive the industry forward to meet efficiency and sustainability goals.”

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less